Skip to main content
Erschienen in: European Radiology 2/2022

24.08.2021 | Breast

Performance of radiomics models for tumour-infiltrating lymphocyte (TIL) prediction in breast cancer: the role of the dynamic contrast-enhanced (DCE) MRI phase

verfasst von: Wen-jie Tang, Qing-cong Kong, Zi-xuan Cheng, Yun-shi Liang, Zhe Jin, Lei-xin Chen, Wen-ke Hu, Ying-ying Liang, Xin-hua Wei, Yuan Guo, Xin-qing Jiang

Erschienen in: European Radiology | Ausgabe 2/2022

Einloggen, um Zugang zu erhalten

Abstract

Objective

To systematically investigate the effect of imaging features at different DCE-MRI phases to optimise a radiomics model based on DCE-MRI for the prediction of tumour-infiltrating lymphocyte (TIL) levels in breast cancer.

Materials and methods

This study retrospectively collected 133 patients with pathologically proven breast cancer, including 73 patients with low TIL levels and 60 patients with high TIL levels. The volumes of breast cancer lesions were manually delineated on T2-weighted imaging (T2WI), diffusion-weighted imaging (DWI), and each phase of DCE-MRI, followed by 6250 quantitative feature extractions. The least absolute shrinkage and selection operator (LASSO) method was used to select predictive feature sets for the classifiers. Four models were developed for predicting TILs: (1) single enhanced phase radiomics models; (2) fusion enhanced multi-phase radiomics models; (3) fusion multi-sequence radiomics models; and (4) a combined radiomics-based clinical model.

Results

Image features extracted from the delayed phase MRI, especially DCE_Phase 6 (DCE_P6), demonstrated dominant predictive performances over features from other phases. The fusion multi-sequence radiomics model and combined radiomics-based clinical model achieved the highest predictive performances with areas under the curve (AUCs) of 0.934 and 0.950, respectively; however, the differences were not statistically significant.

Conclusion

The DCE-MRI radiomics model, especially image features extracted from the delayed phases, can help improve the performance in predicting TILs. The radiomics nomogram is effective in predicting TILs in breast cancer.

Key Points

Radiomics features extracted from DCE-MRI, especially delayed phase images, help predict TIL levels in breast cancer.
We developed a nomogram based on MRI to predict TILs in breast cancer that achieved the highest AUC of 0.950.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Savas P, Salgado R, Denkert C et al (2016) Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nat Rev Clin Oncol 13:228–241CrossRef Savas P, Salgado R, Denkert C et al (2016) Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nat Rev Clin Oncol 13:228–241CrossRef
2.
Zurück zum Zitat Ingold Heppner B, Untch M, Denkert C et al (2016) Tumor-infiltrating lymphocytes: a predictive and prognostic biomarker in neoadjuvant-treated HER2-positive breast cancer. Clin Cancer Res 22:5747–5754CrossRef Ingold Heppner B, Untch M, Denkert C et al (2016) Tumor-infiltrating lymphocytes: a predictive and prognostic biomarker in neoadjuvant-treated HER2-positive breast cancer. Clin Cancer Res 22:5747–5754CrossRef
3.
Zurück zum Zitat Denkert C, Wienert S, Poterie A et al (2016) Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group. Mod Pathol 29:1155–1164CrossRef Denkert C, Wienert S, Poterie A et al (2016) Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group. Mod Pathol 29:1155–1164CrossRef
4.
Zurück zum Zitat Salgado R, Denkert C, Demaria S et al (2015) The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol 26:259–271CrossRef Salgado R, Denkert C, Demaria S et al (2015) The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol 26:259–271CrossRef
5.
Zurück zum Zitat Dieci MV, Radosevic-Robin N, Fineberg S et al (2018) Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: a report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. Semin Cancer Biol 52:16–25CrossRef Dieci MV, Radosevic-Robin N, Fineberg S et al (2018) Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: a report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. Semin Cancer Biol 52:16–25CrossRef
6.
Zurück zum Zitat Bellesoeur A, Torossian N, Amigorena S, Romano E (2020) Advances in theranostic biomarkers for tumor immunotherapy. Curr Opin Chem Biol 56:79–90CrossRef Bellesoeur A, Torossian N, Amigorena S, Romano E (2020) Advances in theranostic biomarkers for tumor immunotherapy. Curr Opin Chem Biol 56:79–90CrossRef
7.
Zurück zum Zitat Dromain C, Beigelman C, Pozzessere C, Duran R, Digklia A (2020) Imaging of tumour response to immunotherapy. Eur Radiol Exp 4:2CrossRef Dromain C, Beigelman C, Pozzessere C, Duran R, Digklia A (2020) Imaging of tumour response to immunotherapy. Eur Radiol Exp 4:2CrossRef
8.
Zurück zum Zitat Celebi F, Agacayak F, Ozturk A et al (2020) Usefulness of imaging findings in predicting tumor-infiltrating lymphocytes in patients with breast cancer. Eur Radiol 30:2049–2057CrossRef Celebi F, Agacayak F, Ozturk A et al (2020) Usefulness of imaging findings in predicting tumor-infiltrating lymphocytes in patients with breast cancer. Eur Radiol 30:2049–2057CrossRef
9.
Zurück zum Zitat Ku YJ, Kim HH, Cha JH et al (2018) Predicting the level of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: usefulness of breast MRI computer-aided detection and diagnosis. J Magn Reson Imaging 47:760–766CrossRef Ku YJ, Kim HH, Cha JH et al (2018) Predicting the level of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: usefulness of breast MRI computer-aided detection and diagnosis. J Magn Reson Imaging 47:760–766CrossRef
10.
Zurück zum Zitat Fogante M, Tagliati C, De Lisa M, Berardi R, Giuseppetti GM, Giovagnoni A (2019) Correlation between apparent diffusion coefficient of magnetic resonance imaging and tumor-infiltrating lymphocytes in breast cancer. Radiol Med 124:581–587CrossRef Fogante M, Tagliati C, De Lisa M, Berardi R, Giuseppetti GM, Giovagnoni A (2019) Correlation between apparent diffusion coefficient of magnetic resonance imaging and tumor-infiltrating lymphocytes in breast cancer. Radiol Med 124:581–587CrossRef
11.
Zurück zum Zitat W-j T, Jin Z, Y-l Z et al (2021) Whole-lesion histogram analysis of the apparent diffusion coefficient as a quantitative imaging biomarker for assessing the level of tumor-infiltrating lymphocytes: value in molecular subtypes of breast cancer. Front Oncol 10:611571CrossRef W-j T, Jin Z, Y-l Z et al (2021) Whole-lesion histogram analysis of the apparent diffusion coefficient as a quantitative imaging biomarker for assessing the level of tumor-infiltrating lymphocytes: value in molecular subtypes of breast cancer. Front Oncol 10:611571CrossRef
12.
Zurück zum Zitat Murakami W, Tozaki M, Sasaki M et al (2020) Correlation between (18)F-FDG uptake on PET/MRI and the level of tumor-infiltrating lymphocytes (TILs) in triple-negative and HER2-positive breast cancer. Eur J Radiol 123:108773CrossRef Murakami W, Tozaki M, Sasaki M et al (2020) Correlation between (18)F-FDG uptake on PET/MRI and the level of tumor-infiltrating lymphocytes (TILs) in triple-negative and HER2-positive breast cancer. Eur J Radiol 123:108773CrossRef
13.
Zurück zum Zitat Cook G, Goh V (2020) A role for FDG PET radiomics in personalized medicine? Semin Nucl Med 50:532–540CrossRef Cook G, Goh V (2020) A role for FDG PET radiomics in personalized medicine? Semin Nucl Med 50:532–540CrossRef
14.
Zurück zum Zitat Ma W, Ji Y, Qi L, Guo X, Jian X, Liu P (2018) Breast cancer Ki67 expression prediction by DCE-MRI radiomics features. Clin Radiol 73:909.e901–909.e905 Ma W, Ji Y, Qi L, Guo X, Jian X, Liu P (2018) Breast cancer Ki67 expression prediction by DCE-MRI radiomics features. Clin Radiol 73:909.e901–909.e905
15.
Zurück zum Zitat Fan M, Yuan W, Zhao W et al (2020) Joint prediction of breast cancer histological grade and Ki-67 expression level based on DCE-MRI and DWI radiomics. IEEE J Biomed Health Inform 24:1632–1642CrossRef Fan M, Yuan W, Zhao W et al (2020) Joint prediction of breast cancer histological grade and Ki-67 expression level based on DCE-MRI and DWI radiomics. IEEE J Biomed Health Inform 24:1632–1642CrossRef
16.
Zurück zum Zitat Liu C, Ding J, Spuhler K et al (2019) Preoperative prediction of sentinel lymph node metastasis in breast cancer by radiomic signatures from dynamic contrast-enhanced MRI. J Magn Reason Imaging 49:131–140CrossRef Liu C, Ding J, Spuhler K et al (2019) Preoperative prediction of sentinel lymph node metastasis in breast cancer by radiomic signatures from dynamic contrast-enhanced MRI. J Magn Reason Imaging 49:131–140CrossRef
17.
Zurück zum Zitat Liu J, Sun D, Chen L et al (2019) Radiomics analysis of dynamic contrast-enhanced magnetic resonance imaging for the prediction of sentinel lymph node metastasis in breast cancer. Front Oncol 9:980CrossRef Liu J, Sun D, Chen L et al (2019) Radiomics analysis of dynamic contrast-enhanced magnetic resonance imaging for the prediction of sentinel lymph node metastasis in breast cancer. Front Oncol 9:980CrossRef
18.
Zurück zum Zitat Braman N, Etesami M, Prasanna P et al (2017) Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI. Breast Cancer Res 19:57CrossRef Braman N, Etesami M, Prasanna P et al (2017) Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI. Breast Cancer Res 19:57CrossRef
19.
Zurück zum Zitat Liu Z, Li Z, Qu J et al (2019) Radiomics of multiparametric MRI for pretreatment prediction of pathologic complete response to neoadjuvant chemotherapy in breast cancer: a multicenter study. Clin Cancer Res 25:3538–3547 Liu Z, Li Z, Qu J et al (2019) Radiomics of multiparametric MRI for pretreatment prediction of pathologic complete response to neoadjuvant chemotherapy in breast cancer: a multicenter study. Clin Cancer Res 25:3538–3547
20.
Zurück zum Zitat Liu Z, Feng B, Li C et al (2019) Preoperative prediction of lymphovascular invasion in invasive breast cancer with dynamic contrast-enhanced-MRI-based radiomics. J Magn Reason Imaging 50:847–857CrossRef Liu Z, Feng B, Li C et al (2019) Preoperative prediction of lymphovascular invasion in invasive breast cancer with dynamic contrast-enhanced-MRI-based radiomics. J Magn Reason Imaging 50:847–857CrossRef
21.
Zurück zum Zitat Denkert C, von Minckwitz G, Darb-Esfahani S et al (2018) Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol 19:40–50CrossRef Denkert C, von Minckwitz G, Darb-Esfahani S et al (2018) Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol 19:40–50CrossRef
22.
Zurück zum Zitat Aerts H, Velazquez E, Leijenaar R et al (2014) Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun 5:4006CrossRef Aerts H, Velazquez E, Leijenaar R et al (2014) Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun 5:4006CrossRef
23.
Zurück zum Zitat Wang J, Kato F, Oyama-Manabe N et al (2015) Identifying triple-negative breast cancer using background parenchymal enhancement heterogeneity on dynamic contrast-enhanced MRI: a pilot radiomics study. PLoS One 10:e0143308CrossRef Wang J, Kato F, Oyama-Manabe N et al (2015) Identifying triple-negative breast cancer using background parenchymal enhancement heterogeneity on dynamic contrast-enhanced MRI: a pilot radiomics study. PLoS One 10:e0143308CrossRef
24.
Zurück zum Zitat Burugu S, Asleh-Aburaya K, Nielsen T (2017) Immune infiltrates in the breast cancer microenvironment: detection, characterization and clinical implication. Breast Cancer 24:3–15CrossRef Burugu S, Asleh-Aburaya K, Nielsen T (2017) Immune infiltrates in the breast cancer microenvironment: detection, characterization and clinical implication. Breast Cancer 24:3–15CrossRef
25.
Zurück zum Zitat Jones E, Sinha S, Newitt D et al (2013) MRI enhancement in stromal tissue surrounding breast tumors: association with recurrence free survival following neoadjuvant chemotherapy. PLoS One 8:e61969CrossRef Jones E, Sinha S, Newitt D et al (2013) MRI enhancement in stromal tissue surrounding breast tumors: association with recurrence free survival following neoadjuvant chemotherapy. PLoS One 8:e61969CrossRef
26.
Zurück zum Zitat Wegner C, Gaustad J, Andersen L, Simonsen T, Rofstad E (2016) Diffusion-weighted and dynamic contrast-enhanced MRI of pancreatic adenocarcinoma xenografts: associations with tumor differentiation and collagen content. J Transl Med 14:161CrossRef Wegner C, Gaustad J, Andersen L, Simonsen T, Rofstad E (2016) Diffusion-weighted and dynamic contrast-enhanced MRI of pancreatic adenocarcinoma xenografts: associations with tumor differentiation and collagen content. J Transl Med 14:161CrossRef
27.
Zurück zum Zitat Cao J, Pickup S, Clendenin C et al (2019) Dynamic contrast-enhanced MRI detects responses to stroma-directed therapy in mouse models of pancreatic ductal adenocarcinoma. Clin Cancer Res 25:2314–2322 Cao J, Pickup S, Clendenin C et al (2019) Dynamic contrast-enhanced MRI detects responses to stroma-directed therapy in mouse models of pancreatic ductal adenocarcinoma. Clin Cancer Res 25:2314–2322
28.
Zurück zum Zitat Asayama Y, Yoshimitsu K, Irie H et al (2006) Delayed-phase dynamic CT enhancement as a prognostic factor for mass-forming intrahepatic cholangiocarcinoma. Radiology 238:150–155CrossRef Asayama Y, Yoshimitsu K, Irie H et al (2006) Delayed-phase dynamic CT enhancement as a prognostic factor for mass-forming intrahepatic cholangiocarcinoma. Radiology 238:150–155CrossRef
29.
Zurück zum Zitat Lacomis J, Baron R, Oliver J, Nalesnik M, Federle M (1997) Cholangiocarcinoma: delayed CT contrast enhancement patterns. Radiology 203:98–104CrossRef Lacomis J, Baron R, Oliver J, Nalesnik M, Federle M (1997) Cholangiocarcinoma: delayed CT contrast enhancement patterns. Radiology 203:98–104CrossRef
30.
Zurück zum Zitat Stanton S, Disis M (2016) Clinical significance of tumor-infiltrating lymphocytes in breast cancer. J Immunother Cancer 4:59CrossRef Stanton S, Disis M (2016) Clinical significance of tumor-infiltrating lymphocytes in breast cancer. J Immunother Cancer 4:59CrossRef
31.
Zurück zum Zitat Saltz J, Gupta R, Hou L et al (2018) Spatial organization and molecular correlation of tumor-infiltrating lymphocytes using deep learning on pathology images. Cell Rep 23:181–193.e187CrossRef Saltz J, Gupta R, Hou L et al (2018) Spatial organization and molecular correlation of tumor-infiltrating lymphocytes using deep learning on pathology images. Cell Rep 23:181–193.e187CrossRef
32.
Zurück zum Zitat Song Q, Shi F, Adair M et al (2019) Cell counts, rather than proportion, of CD8/PD-1 tumor-infiltrating lymphocytes in a tumor microenvironment associated with pathological characteristics of Chinese invasive ductal breast cancer. J Immunol Res 2019:8505021PubMedPubMedCentral Song Q, Shi F, Adair M et al (2019) Cell counts, rather than proportion, of CD8/PD-1 tumor-infiltrating lymphocytes in a tumor microenvironment associated with pathological characteristics of Chinese invasive ductal breast cancer. J Immunol Res 2019:8505021PubMedPubMedCentral
33.
Zurück zum Zitat Huang W, Ran R, Shao B, Li H (2019) Prognostic and clinicopathological value of PD-L1 expression in primary breast cancer: a meta-analysis. Breast Cancer Res Treat 178:17–33CrossRef Huang W, Ran R, Shao B, Li H (2019) Prognostic and clinicopathological value of PD-L1 expression in primary breast cancer: a meta-analysis. Breast Cancer Res Treat 178:17–33CrossRef
34.
Zurück zum Zitat Kim S, Jeong H, Woo O et al (2013) Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer. Am J Clin Oncol 36:224–231CrossRef Kim S, Jeong H, Woo O et al (2013) Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer. Am J Clin Oncol 36:224–231CrossRef
35.
Zurück zum Zitat Solinas C, Carbognin L, De Silva P, Criscitiello C, Lambertini M (2017) Tumor-infiltrating lymphocytes in breast cancer according to tumor subtype: current state of the art. Breast 35:142–150CrossRef Solinas C, Carbognin L, De Silva P, Criscitiello C, Lambertini M (2017) Tumor-infiltrating lymphocytes in breast cancer according to tumor subtype: current state of the art. Breast 35:142–150CrossRef
36.
Zurück zum Zitat Wein L, Savas P, Luen SJ, Virassamy B, Salgado R, Loi S (2017) Clinical validity and utility of tumor-infiltrating lymphocytes in routine clinical practice for breast cancer patients: current and future directions. Front Oncol 7:156CrossRef Wein L, Savas P, Luen SJ, Virassamy B, Salgado R, Loi S (2017) Clinical validity and utility of tumor-infiltrating lymphocytes in routine clinical practice for breast cancer patients: current and future directions. Front Oncol 7:156CrossRef
Metadaten
Titel
Performance of radiomics models for tumour-infiltrating lymphocyte (TIL) prediction in breast cancer: the role of the dynamic contrast-enhanced (DCE) MRI phase
verfasst von
Wen-jie Tang
Qing-cong Kong
Zi-xuan Cheng
Yun-shi Liang
Zhe Jin
Lei-xin Chen
Wen-ke Hu
Ying-ying Liang
Xin-hua Wei
Yuan Guo
Xin-qing Jiang
Publikationsdatum
24.08.2021
Verlag
Springer Berlin Heidelberg
Erschienen in
European Radiology / Ausgabe 2/2022
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-021-08173-5

Weitere Artikel der Ausgabe 2/2022

European Radiology 2/2022 Zur Ausgabe

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

S3-Leitlinie zu Pankreaskrebs aktualisiert

23.04.2024 Pankreaskarzinom Nachrichten

Die Empfehlungen zur Therapie des Pankreaskarzinoms wurden um zwei Off-Label-Anwendungen erweitert. Und auch im Bereich der Früherkennung gibt es Aktualisierungen.

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

18.04.2024 Pädiatrische Notfallmedizin Nachrichten

Im Choosing-Wisely-Programm, das für die deutsche Initiative „Klug entscheiden“ Pate gestanden hat, sind erstmals Empfehlungen zum Umgang mit Notfällen von Kindern erschienen. Fünf Dinge gilt es demnach zu vermeiden.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.